{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:16:11Z","timestamp":1790741771479,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","award":["1091"],"award-info":[{"award-number":["1091"]}],"id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007202","name":"Gouvernement du Canada | Instituts de Recherche en Sant\u00e9 du Canada | CIHR Skin Research Training Centre","doi-asserted-by":"publisher","award":["148373"],"award-info":[{"award-number":["148373"]}],"id":[{"id":"10.13039\/501100007202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007202","name":"Gouvernement du Canada | Instituts de Recherche en Sant\u00e9 du Canada | CIHR Skin Research Training Centre","doi-asserted-by":"publisher","award":["PLL-185690"],"award-info":[{"award-number":["PLL-185690"]}],"id":[{"id":"10.13039\/501100007202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007202","name":"Gouvernement du Canada | Instituts de Recherche en Sant\u00e9 du Canada | CIHR Skin Research Training Centre","doi-asserted-by":"publisher","award":["PJT-190027"],"award-info":[{"award-number":["PJT-190027"]}],"id":[{"id":"10.13039\/501100007202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010785","name":"Canada First Research Excellence Fund","doi-asserted-by":"publisher","award":["A2-021"],"award-info":[{"award-number":["A2-021"]}],"id":[{"id":"10.13039\/501100010785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Co-expression of the estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) contributes to breast cancer heterogeneity and therapeutic resistance. However, the molecular mechanisms promoting ER positivity within HER2+ cancers remains largely unknown. Here we show, across HER2+ transgenic mouse models the oncogenic HER2 splice variant lacking exon 16 (HER2\u220616) promotes the development of aggressive luminal tumors by facilitating an ER-mediated transcriptional program which is sensitive to endocrine therapies. HER2\u220616 is detected across human HER2+ breast tumors and cell lines with higher levels correlating with increased expression of ER and downstream transcriptional targets. Notably, in human cell lines HER2\u220616 expression is elevated upon acquired resistance to HER2-targeted therapy and can sensitize cells to the ER-antagonist tamoxifen. Overall, these findings offer valuable insights into the role of HER2\u220616 in promoting luminal cell identity and estrogen receptor positivity in breast cancer, providing a useful platform to model HER2+\/ER+ disease.<\/jats:p>","DOI":"10.1038\/s41467-026-74435-9","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:04:10Z","timestamp":1781510650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["HER2\u220616 directs luminal cell identity and estrogen receptor signaling in HER2+ breast cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5109-8840","authenticated-orcid":false,"given":"Hailey","family":"Proud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Podleszanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif S.","family":"Attalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0124-1546","authenticated-orcid":false,"given":"Ellie J.","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Taifour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Eric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Pacis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey W.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Papavasiliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Sanguin-Gendreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7293-4166","authenticated-orcid":false,"given":"William J.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"74435_CR1","doi-asserted-by":"publisher","unstructured":"Cheng, X. A Comprehensive Review of HER2 in Cancer Biology and Therapeutics. Genes (Basel) 15. https:\/\/doi.org\/10.3390\/genes15070903 (2024).","DOI":"10.3390\/genes15070903"},{"key":"74435_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas, N","year":"2012","unstructured":"Cancer Genome Atlas, N Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 (2012).","journal-title":"Nature"},{"key":"74435_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235, 177\u2013182 (1987).","journal-title":"Science"},{"key":"74435_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug Discov. 22, 101\u2013126 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"74435_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10555-012-9415-3","volume":"32","author":"Y Mao","year":"2013","unstructured":"Mao, Y., Keller, E. T., Garfield, D. H., Shen, K. & Wang, J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 32, 303\u2013315 (2013).","journal-title":"Cancer Metastasis Rev."},{"key":"74435_CR6","doi-asserted-by":"publisher","first-page":"1111796","DOI":"10.3389\/fcell.2023.1111796","volume":"11","author":"S Attalla","year":"2023","unstructured":"Attalla, S., Taifour, T. & Muller, W. Tailoring therapies to counter the divergent immune landscapes of breast cancer. Front Cell Dev. Biol. 11, 1111796 (2023).","journal-title":"Front Cell Dev. Biol."},{"key":"74435_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1530\/ERC-19-0042","volume":"26","author":"EL Esakov","year":"2019","unstructured":"Esakov, E. L. et al. Therapeutic strategies to induce ERalpha in luminal breast cancer to enhance tamoxifen efficacy. Endocr. Relat. Cancer 26, 689\u2013698 (2019).","journal-title":"Endocr. Relat. Cancer"},{"key":"74435_CR8","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1158\/1078-0432.CCR-21-1317","volume":"27","author":"D Venet","year":"2021","unstructured":"Venet, D. et al. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial. Clin. Cancer Res. 27, 5607\u20135618 (2021).","journal-title":"Clin. Cancer Res."},{"key":"74435_CR9","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.4161\/cc.22225","volume":"11","author":"C Oliveras-Ferraros","year":"2012","unstructured":"Oliveras-Ferraros, C. et al. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle 11, 4020\u20134032 (2012).","journal-title":"Cell Cycle"},{"key":"74435_CR10","doi-asserted-by":"publisher","unstructured":"Hou, Y., Nitta, H. & Li, Z. HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept. Cancers (Basel) 15 https:\/\/doi.org\/10.3390\/cancers15102664 (2023).","DOI":"10.3390\/cancers15102664"},{"key":"74435_CR11","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","volume":"11","author":"OM Filho","year":"2021","unstructured":"Filho, O. M. et al. Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov. 11, 2474\u20132487 (2021).","journal-title":"Cancer Discov."},{"key":"74435_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54621-3","volume":"15","author":"M Rediti","year":"2024","unstructured":"Rediti, M. et al. Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial. Nat. Commun. 15, 10402 (2024).","journal-title":"Nat. Commun."},{"key":"74435_CR13","doi-asserted-by":"publisher","unstructured":"Howlader, N. et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J. Natl. Cancer Inst. 106 https:\/\/doi.org\/10.1093\/jnci\/dju055 (2014).","DOI":"10.1093\/jnci\/dju055"},{"key":"74435_CR14","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1158\/1078-0432.CCR-04-2569","volume":"11","author":"M De Laurentiis","year":"2005","unstructured":"De Laurentiis, M. et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin. Cancer Res. 11, 4741\u20134748 (2005).","journal-title":"Clin. Cancer Res."},{"key":"74435_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/cncr.26162","volume":"118","author":"F Montemurro","year":"2012","unstructured":"Montemurro, F. et al. Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer 118, 17\u201326 (2012).","journal-title":"Cancer"},{"key":"74435_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1530\/ERC-18-0029","volume":"25","author":"B Zhao","year":"2018","unstructured":"Zhao, B., Zhao, H. & Zhao, J. Impact of hormone receptor status on the efficacy of HER2-targeted treatment. Endocr. Relat. Cancer 25, 687\u2013697 (2018).","journal-title":"Endocr. Relat. Cancer"},{"key":"74435_CR17","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1158\/1078-0432.CCR-14-2728","volume":"21","author":"M Giuliano","year":"2015","unstructured":"Giuliano, M. et al. Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy. Clin. Cancer Res. 21, 3995\u20134003 (2015).","journal-title":"Clin. Cancer Res."},{"key":"74435_CR18","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1158\/1535-7163.MCT-09-0295","volume":"8","author":"D Mitra","year":"2009","unstructured":"Mitra, D. et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol. Cancer Ther. 8, 2152\u20132162 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"74435_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jtho.2019.09.006","volume":"15","author":"CC Hsu","year":"2020","unstructured":"Hsu, C. C. et al. Exon 16-skipping HER2 as a novel mechanism of osimertinib resistance in EGFR L858R\/T790M-positive non-small cell lung cancer. J. Thorac. Oncol. 15, 50\u201361 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"74435_CR20","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1093\/emboj\/18.8.2149","volume":"18","author":"PM Siegel","year":"1999","unstructured":"Siegel, P. M., Ryan, E. D., Cardiff, R. D. & Muller, W. J. Elevated expression of activated forms of Neu\/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 18, 2149\u20132164 (1999).","journal-title":"EMBO J."},{"key":"74435_CR21","doi-asserted-by":"publisher","first-page":"855308","DOI":"10.3389\/fonc.2022.855308","volume":"12","author":"S Wang","year":"2022","unstructured":"Wang, S. et al. ERBB2D16 expression in HER2 positive gastric cancer is associated with resistance to trastuzumab. Front Oncol. 12, 855308 (2022).","journal-title":"Front Oncol."},{"key":"74435_CR22","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.1038\/onc.2016.129","volume":"35","author":"J Turpin","year":"2016","unstructured":"Turpin, J. et al. The ErbB2DeltaEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. Oncogene 35, 6053\u20136064 (2016).","journal-title":"Oncogene"},{"key":"74435_CR23","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1158\/2326-6066.CIR-22-0140","volume":"11","author":"SS Attalla","year":"2023","unstructured":"Attalla, S. S. et al. HER2Delta16 engages ENPP1 to promote an immune-cold microenvironment in breast cancer. Cancer Immunol. Res 11, 1184\u20131202 (2023).","journal-title":"Cancer Immunol. Res"},{"key":"74435_CR24","doi-asserted-by":"publisher","first-page":"R319","DOI":"10.1530\/ERC-18-0063","volume":"25","author":"BC Ozdemir","year":"2018","unstructured":"Ozdemir, B. C., Sflomos, G. & Brisken, C. The challenges of modeling hormone receptor-positive breast cancer in mice. Endocr. Relat. Cancer 25, R319\u2013R330 (2018).","journal-title":"Endocr. Relat. Cancer"},{"key":"74435_CR25","doi-asserted-by":"publisher","first-page":"54444","DOI":"10.18632\/oncotarget.17088","volume":"8","author":"A Palladini","year":"2017","unstructured":"Palladini, A. et al. HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. Oncotarget 8, 54444\u201354458 (2017).","journal-title":"Oncotarget"},{"key":"74435_CR26","doi-asserted-by":"publisher","first-page":"vbac016","DOI":"10.1093\/bioadv\/vbac016","volume":"2","author":"IMP Badia","year":"2022","unstructured":"Badia, I. M. P. et al. decoupleR: ensemble of computational methods to infer biological activities from omics data. Bioinform Adv. 2, vbac016 (2022).","journal-title":"Bioinform Adv."},{"key":"74435_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1128\/MCB.00907-09","volume":"30","author":"S Malik","year":"2010","unstructured":"Malik, S. et al. Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM. Mol. Cell Biol. 30, 399\u2013412 (2010).","journal-title":"Mol. Cell Biol."},{"key":"74435_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1023\/A:1012972808558","volume":"70","author":"DO Azorsa","year":"2001","unstructured":"Azorsa, D. O., Cunliffe, H. E. & Meltzer, P. S. Association of steroid receptor coactivator AIB1 with estrogen receptor-alpha in breast cancer cells. Breast Cancer Res Treat. 70, 89\u2013101 (2001).","journal-title":"Breast Cancer Res Treat."},{"key":"74435_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00688-6","volume":"10","author":"J Sandstrom","year":"2024","unstructured":"Sandstrom, J. et al. GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer. NPJ Breast Cancer 10, 78 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"74435_CR30","first-page":"7068","volume":"14","author":"PM Siegel","year":"1994","unstructured":"Siegel, P. M., Dankort, D. L., Hardy, W. R. & Muller, W. J. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell Biol. 14, 7068\u20137077 (1994).","journal-title":"Mol. Cell Biol."},{"key":"74435_CR31","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1073\/pnas.97.7.3444","volume":"97","author":"ER Andrechek","year":"2000","unstructured":"Andrechek, E. R. et al. Amplification of the neu\/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc. Natl. Acad. Sci. USA 97, 3444\u20133449 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74435_CR32","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1158\/0008-5472.CAN-12-3186","volume":"73","author":"A Alajati","year":"2013","unstructured":"Alajati, A. et al. Mammary tumor formation and metastasis evoked by a HER2 splice variant. Cancer Res. 73, 5320\u20135327 (2013).","journal-title":"Cancer Res."},{"key":"74435_CR33","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.molonc.2012.10.012","volume":"7","author":"KK Sahlberg","year":"2013","unstructured":"Sahlberg, K. K. et al. The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. Mol. Oncol. 7, 392\u2013401 (2013).","journal-title":"Mol. Oncol."},{"key":"74435_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/j.1460-2075.1987.tb04763.x","volume":"6","author":"AC Cato","year":"1987","unstructured":"Cato, A. C., Henderson, D. & Ponta, H. The hormone response element of the mouse mammary tumour virus DNA mediates the progestin and androgen induction of transcription in the proviral long terminal repeat region. EMBO J. 6, 363\u2013368 (1987).","journal-title":"EMBO J."},{"key":"74435_CR35","doi-asserted-by":"publisher","first-page":"106517","DOI":"10.1016\/j.jsbmb.2024.106517","volume":"240","author":"C McGuinness","year":"2024","unstructured":"McGuinness, C. & Britt, K. L. Estrogen receptor regulation of the immune microenvironment in breast cancer. J. Steroid Biochem Mol. Biol. 240, 106517 (2024).","journal-title":"J. Steroid Biochem Mol. Biol."},{"key":"74435_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/BF01525437","volume":"37","author":"E Robinson","year":"1993","unstructured":"Robinson, E., Rubin, D., Mekori, T., Segal, R. & Pollack, S. In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer. Cancer Immunol. Immunother. 37, 209\u2013212 (1993).","journal-title":"Cancer Immunol. Immunother."},{"key":"74435_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40310-5","volume":"9","author":"CC Volpi","year":"2019","unstructured":"Volpi, C. C. et al. The landscape of d16HER2 splice variant expression across HER2-positive cancers. Sci. Rep. 9, 3545 (2019).","journal-title":"Sci. Rep."},{"key":"74435_CR38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1677\/erc.1.01047","volume":"13","author":"F Castiglioni","year":"2006","unstructured":"Castiglioni, F. et al. Role of exon-16-deleted HER2 in breast carcinomas. Endocr. Relat. Cancer 13, 221\u2013232 (2006).","journal-title":"Endocr. Relat. Cancer"},{"key":"74435_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10549-010-1281-5","volume":"130","author":"G Valabrega","year":"2011","unstructured":"Valabrega, G. et al. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Res. Treat. 130, 29\u201340 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"74435_CR40","doi-asserted-by":"publisher","unstructured":"Castagnoli, L., Ladomery, M., Tagliabue, E. & Pupa, S. M. The d16HER2 splice variant: a friend or foe of HER2-positive cancers? Cancers (Basel) 11 https:\/\/doi.org\/10.3390\/cancers11070902 (2019).","DOI":"10.3390\/cancers11070902"},{"key":"74435_CR41","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/sj.onc.1202107","volume":"17","author":"JM Knowlden","year":"1998","unstructured":"Knowlden, J. M. et al. c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 17, 1949\u20131957 (1998).","journal-title":"Oncogene"},{"key":"74435_CR42","doi-asserted-by":"publisher","first-page":"7991","DOI":"10.1158\/0008-5472.CAN-05-4397","volume":"66","author":"Y Zhu","year":"2006","unstructured":"Zhu, Y. et al. Coregulation of estrogen receptor by ERBB4\/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res 66, 7991\u20137998 (2006).","journal-title":"Cancer Res"},{"key":"74435_CR43","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1080\/15476286.2015.1076610","volume":"12","author":"H Gautrey","year":"2015","unstructured":"Gautrey, H. et al. SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells. RNA Biol. 12, 1139\u20131151 (2015).","journal-title":"RNA Biol."},{"key":"74435_CR44","doi-asserted-by":"publisher","first-page":"577636","DOI":"10.3389\/fonc.2020.577636","volume":"10","author":"Z Zhou","year":"2020","unstructured":"Zhou, Z. et al. Emerging roles of SRSF3 as a therapeutic target for cancer. Front Oncol. 10, 577636 (2020).","journal-title":"Front Oncol."},{"key":"74435_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27093-y","volume":"12","author":"AE Smith","year":"2021","unstructured":"Smith, A. E. et al. HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nat. Commun. 12, 6667 (2021).","journal-title":"Nat. Commun."},{"key":"74435_CR46","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3892\/ol.2013.1324","volume":"6","author":"M Chen","year":"2013","unstructured":"Chen, M., Cui, Y. K., Huang, W. H., Man, K. & Zhang, G. J. Phosphorylation of estrogen receptor alpha at serine 118 is correlated with breast cancer resistance to tamoxifen. Oncol. Lett. 6, 118\u2013124 (2013).","journal-title":"Oncol. Lett."},{"key":"74435_CR47","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.ejca.2012.11.020","volume":"49","author":"LM McGlynn","year":"2013","unstructured":"McGlynn, L. M. et al. Interactions between MAP kinase and oestrogen receptor in human breast cancer. Eur. J. Cancer 49, 1176\u20131186 (2013).","journal-title":"Eur. J. Cancer"},{"key":"74435_CR48","doi-asserted-by":"publisher","first-page":"14681","DOI":"10.1074\/jbc.M112.349357","volume":"287","author":"X Qi","year":"2012","unstructured":"Qi, X. et al. p38gamma mitogen-activated protein kinase (MAPK) confers breast cancer hormone sensitivity by switching estrogen receptor (ER) signaling from classical to nonclassical pathway via stimulating ER phosphorylation and c-Jun transcription. J. Biol. Chem. 287, 14681\u201314691 (2012).","journal-title":"J. Biol. Chem."},{"key":"74435_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00533-2","volume":"9","author":"M Pegram","year":"2023","unstructured":"Pegram, M., Jackisch, C. & Johnston, S. R. D. Estrogen\/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive\/HER2-positive breast cancer. NPJ Breast Cancer 9, 45 (2023).","journal-title":"NPJ Breast Cancer"},{"key":"74435_CR50","first-page":"4920","volume":"63","author":"ER Andrechek","year":"2003","unstructured":"Andrechek, E. R. et al. Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Cancer Res. 63, 4920\u20134926 (2003).","journal-title":"Cancer Res."},{"key":"74435_CR51","first-page":"5151","volume":"13","author":"DHN Binh","year":"2023","unstructured":"Binh, D. H. N. et al. StAR-related lipid transfer domain protein 3 (STARD3) regulates HER2 and promotes HER2-positive breast cancer progression through interaction with HSP90 and SRC signaling. Am. J. Cancer Res. 13, 5151\u20135173 (2023).","journal-title":"Am. J. Cancer Res."},{"key":"74435_CR52","doi-asserted-by":"publisher","first-page":"29279","DOI":"10.1074\/jbc.C110.114124","volume":"285","author":"PY Chu","year":"2010","unstructured":"Chu, P. Y., Li, T. K., Ding, S. T., Lai, I. R. & Shen, T. L. EGF-induced Grb7 recruits and promotes Ras activity essential for the tumorigenicity of Sk-Br3 breast cancer cells. J. Biol. Chem. 285, 29279\u201329285 (2010).","journal-title":"J. Biol. Chem."},{"key":"74435_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01690-9","volume":"25","author":"NG Martinez-Illescas","year":"2023","unstructured":"Martinez-Illescas, N. G. et al. miR-203 drives breast cancer cell differentiation. Breast Cancer Res. 25, 91 (2023).","journal-title":"Breast Cancer Res."},{"key":"74435_CR54","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1093\/nar\/gkv1500","volume":"44","author":"M Ajiro","year":"2016","unstructured":"Ajiro, M., Jia, R., Yang, Y., Zhu, J. & Zheng, Z. M. A genome landscape of SRSF3-regulated splicing events and gene expression in human osteosarcoma U2OS cells. Nucleic Acids Res. 44, 1854\u20131870 (2016).","journal-title":"Nucleic Acids Res."},{"key":"74435_CR55","doi-asserted-by":"publisher","first-page":"103695","DOI":"10.1016\/j.esmoop.2024.103695","volume":"9","author":"P Zagami","year":"2024","unstructured":"Zagami, P., Cortes, J., Carey, L. A. & Curigliano, G. Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?. ESMO Open 9, 103695 (2024).","journal-title":"ESMO Open"},{"key":"74435_CR56","doi-asserted-by":"publisher","first-page":"105186","DOI":"10.1016\/j.ebiom.2024.105186","volume":"105","author":"H Li","year":"2024","unstructured":"Li, H. et al. Clinical efficacy of CDK4\/6 inhibitor plus endocrine therapy in HR-positive\/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials. EBioMedicine 105, 105186 (2024).","journal-title":"EBioMedicine"},{"key":"74435_CR57","doi-asserted-by":"publisher","unstructured":"Kciuk, M., Gielecinska, A., Budzinska, A., Mojzych, M. & Kontek, R. Metastasis and MAPK Pathways. Int. J. Mol. Sci. 23 https:\/\/doi.org\/10.3390\/ijms23073847 (2022).","DOI":"10.3390\/ijms23073847"},{"key":"74435_CR58","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1096\/fj.01-0551com","volume":"16","author":"EJ Gunther","year":"2002","unstructured":"Gunther, E. J. et al. A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J. 16, 283\u2013292 (2002).","journal-title":"FASEB J."},{"key":"74435_CR59","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1093\/nar\/25.21.4323","volume":"25","author":"KU Wagner","year":"1997","unstructured":"Wagner, K. U. et al. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res. 25, 4323\u20134330 (1997).","journal-title":"Nucleic Acids Res."},{"key":"74435_CR60","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1101\/gad.339424.120","volume":"34","author":"AM Simond","year":"2020","unstructured":"Simond, A. M. et al. Point-activated ESR1(Y541S) has a dramatic effect on the development of sexually dimorphic organs. Genes Dev. 34, 1304\u20131309 (2020).","journal-title":"Genes Dev."},{"key":"74435_CR61","doi-asserted-by":"publisher","first-page":"15559","DOI":"10.1073\/pnas.1003034107","volume":"107","author":"L Huck","year":"2010","unstructured":"Huck, L., Pontier, S. M., Zuo, D. M. & Muller, W. J. Beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc. Natl. Acad. Sci. USA 107, 15559\u201315564 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74435_CR62","doi-asserted-by":"publisher","first-page":"107571","DOI":"10.1016\/j.celrep.2020.107571","volume":"31","author":"B Xiao","year":"2020","unstructured":"Xiao, B. et al. Rheb1-independent activation of mTORC1 in mammary tumors occurs through activating mutations in mTOR. Cell Rep. 31, 107571 (2020).","journal-title":"Cell Rep."},{"key":"74435_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinforma. 14, 128 (2013).","journal-title":"BMC Bioinforma."},{"key":"74435_CR64","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90\u2013W97 (2016).","journal-title":"Nucleic Acids Res."},{"key":"74435_CR65","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie, Z. et al. Gene set knowledge discovery with enrichr. Curr. Protoc. 1, e90 (2021).","journal-title":"Curr. Protoc."},{"key":"74435_CR66","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1038\/s41388-022-02323-9","volume":"41","author":"AM Simond","year":"2022","unstructured":"Simond, A. M. et al. Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer. Oncogene 41, 3445\u20133451 (2022).","journal-title":"Oncogene"},{"key":"74435_CR67","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41388-021-02107-7","volume":"41","author":"T Bui","year":"2022","unstructured":"Bui, T. et al. Emergence of beta1 integrin-deficient breast tumours from dormancy involves both inactivation of p53 and generation of a permissive tumour microenvironment. Oncogene 41, 527\u2013537 (2022).","journal-title":"Oncogene"},{"key":"74435_CR68","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1002\/ijc.32369","volume":"145","author":"JT Fekete","year":"2019","unstructured":"Fekete, J. T. & Gyorffy, B. ROCplot.org: validating predictive biomarkers of chemotherapy\/hormonal therapy\/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients. Int J. Cancer 145, 3140\u20133151 (2019).","journal-title":"Int J. Cancer"},{"key":"74435_CR69","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1016\/j.csbj.2021.07.014","volume":"19","author":"B Gyorffy","year":"2021","unstructured":"Gyorffy, B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct. Biotechnol. J. 19, 4101\u20134109 (2021).","journal-title":"Comput Struct. Biotechnol. J."},{"key":"74435_CR70","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509\u2013W514 (2020).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74435-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74435-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74435-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:09:14Z","timestamp":1785517754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74435-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74435"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74435-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"At the time of publication, S.S.A. is an employee of Genentech, a member of Roche Group.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7532"}}